25. Kukla M, Adrych K, Dobrowolska A, Mach,T, Reguła J, Rydzewska G. Guidelines for Clostridium difficile infection in adults. Gastroenterology Rev 2020; 15 (1): 1–21. doi: 10.5114/pg.2020.93629
26. Guh AY, Kutty PK. Clostridioides difficile Infection. Ann Intern Med. 2018;169(7):ITC49-ITC64. doi: 10.7326/AITC201810020
27. Kelly CR, Fischer M, Allegretti JR, LaPlante K, Stewart DB, Limketkai BN, Stollman NH. ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections. Am J Gastroenterol. 2021;116(6):1124-1147. doi: 10.14309/ajg.0000000000001278. 2022;28(12):1204-1219. doi: 10.3748/wjg.v28.i12.1204
28. Mamieva Z, Poluektova E, Svistushkin V, Sobolev V, Shifrin O, Guarner F, Ivashkin V. Antibiotics, gut microbiota, and irritable bowel syndrome: What are the relations? World J Gastroenterol. 2022;28(12):1204-1219. doi: 10.3748/wjg.v28.i12.1204
29. Kampouri E, Croxatto A, Prod’hom G, Guery B. Clostridioides difficile Infection, Still a Long Way to Go. J Clin Med. 2021;10(3):389. doi: 10.3390/jcm10030389
30. Шелыгин Ю.А., Алёшкин В.А., Сухина М.А., Миронов А.Ю., Брико Н.И., Козлов Р.С. и соавт. Клинические рекомендации национальной ассоциации специалистов по контролю инфекций, связанных с оказанием медицинской помощи и общероссийской общественной некоммерческой организации «ассоциации колопроктологов россии» по диагностике, лечению и профилактике clostridium difficile-ассоциированной диареи (CDI). Колопроктология, 2018;65(3):7-23. doi: 10.33878/2073-7556-2018-0-3-7-23
31. C.Carroll Karen, Mizusawa Masako. Laboratory Tests for the Diagnosis of Clostridium difficile. Clin Colon Rectal Surg. 2020;33(2):73-81. doi: 10.1055/s-0039-3400476
32. Драпкина О.М., Лазебник Л.Б., Бакулин И.Г., Журавлева М.С., и др. Инфекция Clostridioides difficile: диагностика, лечение и профилактика Клинические рекомендации Российского научного медицинского общества терапевтов, Научного общества гастроэнтерологов России, Общества гастроэнтерологов и гепатологов «Северо-Запад». Экспериментальная и клиническая гастроэнтерология. 2023;(2):4-32. https://doi.org/10.31146/1682-8658-ecg-210-2-4-32
33. Sucher A, Biehle L., Smith A., Tran C. Updated Clinical Practice Guidelines for C difficile Infection in Adults. Allana Sucher et al., US Pharmacist, 46 (12), 2021: HS10- HS16
34. Mattana M, Tomasello R, Cammarata C, Di Carlo P, Fasciana T, Giordano G, Lucchesi A, Siragusa S, Napolitano M. Clostridium difficile Induced Inflammasome Activation and Coagulation Derangements. Microorganisms. 2022 Aug 10;10(8):1624. doi: 10.3390/microorganisms10081624. PMID: 36014040; PMCID: PMC9416296.
35. Iffland, A.; Zechel, M.; Lewejohann, J.-C.; Edel, B.; Hagel, S.; Hartmann, M.; Löffler, B.; Rödel, J. Experience with PCR Testing for Enteric Bacteria and Viruses of Emergency Department Patients with Acute Gastroenteritis: Are There Implications for the Early Treatment of Clostridioides difficile Infection? Antibiotics 2024, 13, 243. https://doi.org/10.3390/ antibiotics13030243
36. Nelson RL, Suda KJ, Evans CT. Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults. Cochrane Database of Systematic Reviews. 2017;3(3): CD004610. doi: 10.1002/14651858.CD004610.pub5
37. Bass SN, Lam SW, Bauer SR, Neuner EA. Comparison of oral vancomycin capsule and solution for treatment of initial episode of severe Clostridium difficile Infection. J Pharm Pract. 2015;28(2):183-188. doi: 10.1177/0897190013515925
38 uon C, Wannier R, Sterken D, Fang MC., Wolf J, Prasad PA. Are Antimotility Agents Safe for Use in Clostridioides difficile Infections? Results From an Observational Study in Malignant Hematology Patients. Mayo Clin Proc Inn Qual Out. 2020;4(6):792-800. doi:: 10.1016/j.mayocpiqo.2020.06.005
39. Johnson S, Louie TJ, Gerding DN, Cornely OA, Chasan – Taber S, Fitts D, Gelone SP, Broom C, Davidson DM. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin Infect Dis. 2014;59:345–354 . doi: 10.1093/cid/ciu313
40. Waqas M, Mohib K, Saleem A, LNU M, Arjumand S, Khalil HH, Nosheen R, Abbas S, Maqsood KM, Abbas K. Rifaximin Therapy for Patients With Metronidazole-Unresponsive Clostridium difficile Infection. Cureus. 2022 ;14(4):e24140. doi: 10.7759/cureus.24140.
41. Sirbu BD, Soriano MM, Manzo C, Lum J, Gerding DN, Johnson S. Vancomycin Taper and Pulse Regimen With Careful Follow-up for Patients With Recurrent Clostridium difficile Infection. Clin Infect Dis. 2017;65(8):1396–1399. doi: 10.1093/cid/cix529
42. Major G, Bradshaw L, Boota N, Sprange K, Diggle M, Montgomery A, Jawhari A, Spiller RC. Follow-on RifAximin for the Prevention of recurrence following standard treatment of Infection with Clostridium Difficile (RAPID): a randomised placebo controlled trial. Gut. 2019; 68(7):1224–1231. doi: 10.1136/gutjnl-2018-316794
43. Garey KW, Ghantoji SS, Shah DN, Habib M, Arora V, Jiang ZD, Du Pont HL. A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. J Antimicrob Chemother. 2011;66(12):2850-5. doi: 10.1093/jac/dkr377.
44. Ng Qin X, Loke W, Foo NX, Yin M, Yeo WS, Soh AYS. A systematic review of the use of rifaximin for Clostridium difficile infections. Anaerobe. 2019;55:35-39. doi: 10.1016/j.anaerobe.2018.10.011
45. Neal MD, Alverdy JC, Hall DE, Simmons RL, Zuckerbraun BS. Diverting loop ileostomy and colonic lavage: an alternative to total abdominal colectomy for the treatment of severe, complicated Clostridium difficile associated disease. Ann Surg. 2011;254(3):423-7; discussion 427-9. doi: 10.1097/SLA.0b013e31822ade48